ZA956849B - Use of a defective recombinant adenovirus in gene therapy - Google Patents

Use of a defective recombinant adenovirus in gene therapy

Info

Publication number
ZA956849B
ZA956849B ZA956849A ZA956849A ZA956849B ZA 956849 B ZA956849 B ZA 956849B ZA 956849 A ZA956849 A ZA 956849A ZA 956849 A ZA956849 A ZA 956849A ZA 956849 B ZA956849 B ZA 956849B
Authority
ZA
South Africa
Prior art keywords
gene therapy
recombinant adenovirus
defective recombinant
defective
adenovirus
Prior art date
Application number
ZA956849A
Other languages
English (en)
Inventor
Didier Branellec
Patrice Denefle
Michel Perricaudet
Jean-Francois Dedieu
Laurent Feldman
Gabriel Steg
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA956849B publication Critical patent/ZA956849B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA956849A 1994-08-17 1995-08-16 Use of a defective recombinant adenovirus in gene therapy ZA956849B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9410083A FR2723697B1 (fr) 1994-08-17 1994-08-17 Methode de traitement de la restenose par la therapie genique

Publications (1)

Publication Number Publication Date
ZA956849B true ZA956849B (en) 1996-04-15

Family

ID=9466347

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA956849A ZA956849B (en) 1994-08-17 1995-08-16 Use of a defective recombinant adenovirus in gene therapy

Country Status (12)

Country Link
US (2) US6410011B1 (no)
EP (1) EP0734448A1 (no)
JP (1) JPH09504558A (no)
AU (1) AU3169495A (no)
CA (1) CA2174232A1 (no)
FI (1) FI961666A (no)
FR (1) FR2723697B1 (no)
IL (1) IL114982A (no)
MX (1) MX9601368A (no)
NO (1) NO317720B1 (no)
WO (1) WO1996005321A1 (no)
ZA (1) ZA956849B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
DK0885002T3 (da) * 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
DE19620308A1 (de) * 1996-05-10 1997-11-13 Franz Wolfgang M Dr Vektor-System zur spezifischen in vivo Genexpression in glatten Gefäßmuskelzellen
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6398757B1 (en) 1997-02-07 2002-06-04 Leuven Research & Development Vzw Gene therapeutic treatment of blood vessel associated disorders
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
ATE344322T1 (de) 1998-02-13 2006-11-15 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
AU759016B2 (en) 1998-10-05 2003-04-03 Penn State Research Foundation, The Compositions and methods for enhancing receptor-mediated cellular internalization
AU776067B2 (en) * 1999-03-04 2004-08-26 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
WO2001055362A2 (en) * 2000-01-31 2001-08-02 The Governement Of The United States Of America, As Represented By The Secretary, Departement Of Health & Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
WO2002061104A2 (en) 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
WO2002080977A1 (en) * 2001-04-04 2002-10-17 Delsitech Oy Biodegradable carrier and method for preparation thereof
WO2003083105A1 (fr) * 2002-03-28 2003-10-09 Medicalseed Co., Ltd. Traitement et prevention de l'angiostenose
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
WO2011032100A1 (en) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP1321526A3 (en) * 1992-11-18 2003-07-02 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
WO1994027612A1 (en) * 1993-05-20 1994-12-08 Baylor College Of Medicine Genetic therapy for cardiovascular disease
CN1115414C (zh) * 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 用于基因治疗的病毒载体
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6780406B1 (en) * 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy

Also Published As

Publication number Publication date
AU3169495A (en) 1996-03-07
IL114982A (en) 2006-10-31
FR2723697B1 (fr) 1996-09-20
CA2174232A1 (fr) 1996-02-22
EP0734448A1 (fr) 1996-10-02
IL114982A0 (en) 1995-12-08
FR2723697A1 (fr) 1996-02-23
NO961504L (no) 1996-04-16
MX9601368A (es) 1998-06-30
NO961504D0 (no) 1996-04-16
FI961666A (fi) 1996-06-06
US6410011B1 (en) 2002-06-25
WO1996005321A1 (fr) 1996-02-22
NO317720B1 (no) 2004-12-02
FI961666A0 (fi) 1996-04-16
JPH09504558A (ja) 1997-05-06
US20020094324A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
ZA956849B (en) Use of a defective recombinant adenovirus in gene therapy
ZA949104B (en) Recombinant viruses and their use in gene therapy
ZA958686B (en) Viral vectors and use in gene therapy
GB2320190B (en) Total hormone replacement therapy
IL105914A0 (en) Methods and compositions for in vivo gene therapy
PL322589A1 (en) Radiotracer-labelled peptides for use in diagnostics and therapy
EP0701499A4 (en) IMPROVED POLISHING CUSHION AND METHOD FOR USE THEREOF
IL112860A0 (en) Recombinant viruses their preparation and their therapeutic uses
IL116816A0 (en) Recombinant defective adenoviruses
ZA9710339B (en) Xanthines and their therapeutic use
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
AU2254597A (en) Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
ZA945012B (en) Viral vectors and their use in gene therapy
ZA949103B (en) Recombinant viruses and their use in gene therapy
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
GB9419021D0 (en) Therapeutic protein
GB9405629D0 (en) Recombinant DNA for use in yeast
IL112993A0 (en) Recombinant niruses, their preparation and their use in gene therapy
IL113725A0 (en) Preparing recombinant aprotini and its variants
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
ZA952244B (en) Recombinant viruses their preparation and their use in gene therapy
GB9421223D0 (en) Tissue imaging in gene therapy
ZA952286B (en) Recombinant viruses their preparation and their use in gene therapy
LTIP1981A (en) Pack for use in for horminal replacement therapy